Form 8-K - Current report:
SEC Accession No. 0001213900-25-042024
Filing Date
2025-05-12
Accepted
2025-05-12 16:05:54
Documents
16
Period of Report
2025-05-08
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea024173301-8k_relmada.htm   iXBRL 8-K 28590
2 LETTER FROM MARCUM LLP ea024173301-8kex16i_relmada.htm EX-16.1 4483
6 GRAPHIC image_1.jpg GRAPHIC 6806
7 GRAPHIC image_2.jpg GRAPHIC 3187
  Complete submission text file 0001213900-25-042024.txt   222414

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE rlmd-20250508.xsd EX-101.SCH 3011
4 XBRL LABEL FILE rlmd-20250508_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE rlmd-20250508_pre.xml EX-101.PRE 22356
18 EXTRACTED XBRL INSTANCE DOCUMENT ea024173301-8k_relmada_htm.xml XML 3694
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

EIN.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39082 | Film No.: 25934752
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)